Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7

Cui, Danli; Huang, Yan; Mao, Shengya; Chen, S C; Qiu, Maixuan; Ji, Lei; Yi, Cheng

doi:10.1590/s0100-879x2009000900013

Cited by 14 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it is important to develop new strategies to overcome this type of resistance in tumor cells. Interestingly, some groups have described the ability of subtoxic concentrations of chemotherapeutic drugs to sensitize tumor cells resistant to TRAIL [23,25,26]. Also the anticancer efficacy of TRAIL against BC cells is known to be retained in the bone microenvironment, even in the present of biologically active OPG at a supraphysiologic concentration [18].…”

Section: Introductionmentioning

confidence: 99%

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

et al. 2012

View full text Add to dashboard Cite

BackgroundWhile breast cancer (BC) is the major cause of death among women worldwide, there is no guarantee of better patient survival because many of these patients develop primarily metastases, despite efforts to detect it in its early stages. Bone metastasis is a common complication that occurs in 65-80 % of patients with disseminated disease, but the molecular basis underlying dormancy, dissemination and establishment of metastasis is not understood. Our objective has been to evaluate simultaneously osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), stromal cell-derived factor-1 (SDF-1), and their receptors (R) in 2 human BC cell lines, MDA-MB-231 and MCF-7.MethodsOPG, RANKL, TRAIL and SDF-1 expression and release, in addition to the expression of their receptors has been investigated using immunofluorescence, immunocytochemistry and ELISA analyses.ResultsMCF-7 cells released higher levels of OPG in conditioned media (CM) than MDA-MB-231 cells; 100 % of both types of cell expressed OPG, RANKL, TRAIL and SDF-1. Moreover, 100 % in both lines expressed membrane RANKL and RANK, whereas only 50 % expressed CXCR4. Furthermore, 100 % expressed TRAIL-R1 and R4, 30-50 % TRAIL-R2, and 40-55 % TRAIL-R3.ConclusionsMCF-7 and MDA-MB-231 cells not only released OPG, but expressed RANKL, TRAIL and SDF-1. The majority of the cells also expressed RANK, CXCR4 and TRAIL-R. Since these ligands and their receptors are implicated in the regulation of proliferation, survival, migration and future bone metastasis during breast tumor progression, assessment of these molecules in tumor biopsies of BC patients could be useful in identifying patients with more aggressive tumors that are also at risk of bone metastasis, which may thus improve the available options for therapeutic intervention.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

et al. 2012

View full text Add to dashboard Cite

show abstract

“…TRAIL, which is able to selectively induce apoptosis in cancer cells, is a potential targeted drug for cancer therapy (20). However, its clinical use is limited by cellular resistance to cell death which occurs in ~50% of cancer cells (21).…”

Section: Discussionmentioning

confidence: 99%

TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo

Zhu

Yan

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The aim of the present study was to prepare a tumor necrosis factor ligand superfamily member 10 (TRAIL) mutant membrane penetrating peptide alike (TMPPA), TRAIL‑Mu3, and to investigate its antitumor effects in colorectal cancer in vitro and in vivo. The pMD19/TRAIL plasmid with designed primers was amplified to construct the target gene; it was ligated with an expression plasmid and the expression was confirmed. Subsequently, TRAIL‑Mu3 was purified and further confirmed by western blot analysis. Immunofluorescence analysis was used to detect the distribution of TRAIL‑Mu3 in colorectal cancer cells. In addition, the present study investigated the antitumor effects of TRAIL‑Mu3 on colorectal cancer in vitro and in vivo. A novel TMPPA, TRAIL‑Mu3, was synthesized in the present study. Following a series of detection experiments, it was confirmed that the TRAIL‑Mu3 gene was obtained and was able to express TRAIL‑Mu3 successfully. The immunofluorescence analysis demonstrated that TRAIL‑Mu3 exhibited a markedly enhanced affinity to the colorectal cancer cell surface. In addition, TRAIL‑Mu3 exerted stronger antitumor effects, compared with TRAIL, on colorectal cancer in vitro and in vivo.

show abstract

“…The sensitivity of cells to drug is evaluated by the value of IC 50 . IC 50 < 10 μ g/mL, which indicates that cells are sensitive to drug, while IC 50 ≥ 10 μ g/mL, which suggests that cells are relatively resistant to drug [20]. …”

Section: Methodsmentioning

confidence: 99%

The Synergistic Effects of Low Dose Fluorouracil and TRAIL on TRAIL-Resistant Human Gastric Adenocarcinoma AGS Cells

Zhu

Huang

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

The TNF-related apoptosis-inducing ligand (TRAIL) is a TNF family member which has been under intense focus because of its remarkable ability to induce apoptosis in malignant human cells while leaving normal cells unscathed. However, many cancer cells remain resistant to TRAIL. In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms. Cell viability was analyzed by sulforhodamine B (SRB) assay and the synergistic effects were evaluated by Jin's formula and confirmed by both morphological changes under inverted microscope and flow cytometry. The expression of TRAIL-R1 (death receptor 4, DR4), TRAIL-R2 (DR5), TRAIL-R3 (decoy receptor, DcR1), TRAIL-R4 (DcR2), procaspase-3, procaspase-8, and procaspase-9 was detected by western blotting. Our results showed that there were significant synergistic effects of low dose 5-Fu and TRAIL on TRAIL-resistant AGS cells, and this effect was supposed to be mediated by decreasing DcR2 expression and increasing DR5 expression. The extrinsic and intrinsic apoptosis pathways were both activated. The data suggest that combined treatment of low dose 5-Fu and TRAIL can be an effective therapeutic approach for gastric adenocarcinoma.

show abstract

Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7

Cited by 14 publications

References 28 publications

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo

The Synergistic Effects of Low Dose Fluorouracil and TRAIL on TRAIL-Resistant Human Gastric Adenocarcinoma AGS Cells

Contact Info

Product

Resources

About